HLA-A and cervical carcinoma: Overall, our results suggest that the combined treatment of ENB101-LNP and cisplatin not only inhibits cell proliferation but also enhances HLA-A expression, promoting antigen presentation and stimulating an immune response against cervical cancer cells.